Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTXNASDAQ:RZLTNASDAQ:SLRNOTCMKTS:TRLPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$4.14$3.94$2.94▼$10.25$230.77M3.13141,045 shs70,400 shsRZLTRezolute$3.89-0.3%$3.27$2.22▼$6.19$236.09M1.01589,097 shs431,957 shsSLRNAcelyrin$2.27$2.36$1.85▼$7.25$229.17M1.071.24 million shsN/ATRLPFAcerus Pharmaceuticals$0.22$0.22$0.08▼$0.34$56.90M2.65,474 shsN/AA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics0.00%-6.55%-11.54%-20.84%-33.44%RZLTRezolute-0.26%+8.96%-2.09%-14.13%+38.43%SLRNAcelyrin0.00%+0.89%+0.89%-12.69%-49.78%TRLPFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFHTXFoghorn Therapeutics2.4828 of 5 stars3.63.00.00.02.31.70.6RZLTRezolute2.6178 of 5 stars3.62.00.00.02.54.20.0SLRNAcelyrin3.4902 of 5 stars3.24.00.00.03.43.31.3TRLPFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 3.13Buy$12.13192.87% UpsideRZLTRezolute 3.14Buy$12.14212.16% UpsideSLRNAcelyrin 2.40Hold$9.60322.91% UpsideTRLPFAcerus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRLPF, RZLT, SLRN, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.004/30/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.004/30/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/23/2025FHTXFoghorn TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/23/2025FHTXFoghorn TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform$9.004/23/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$9.003/7/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$22.60M10.21N/AN/A($1.83) per share-2.26RZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ASLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ATRLPFAcerus Pharmaceuticals$7.38M7.71N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$98.43M-$1.36N/AN/AN/A-357.53%N/A-30.98%N/ARZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.27%-62.41%N/ASLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%8/12/2025 (Estimated)TRLPFAcerus Pharmaceuticals-$18.79M-$0.08N/A∞N/A-254.66%-346.72%-94.54%N/ALatest TRLPF, RZLT, SLRN, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/14/2025Q1 2025SLRNAcelyrin-$0.95-$0.55+$0.40-$0.55N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A3/19/2025Q4 2024SLRNAcelyrin-$0.86-$0.79+$0.07-$0.79N/AN/A3/6/2025Q4 2024FHTXFoghorn Therapeutics-$0.43-$0.30+$0.13-$0.30$8.56 million$2.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ATRLPFAcerus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A4.774.77RZLTRezoluteN/A9.309.30SLRNAcelyrinN/A7.157.15TRLPFAcerus Pharmaceuticals0.641.350.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%RZLTRezolute82.97%SLRNAcelyrin87.31%TRLPFAcerus Pharmaceuticals0.02%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics7.58%RZLTRezolute18.39%SLRNAcelyrin13.60%TRLPFAcerus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12055.74 million50.57 millionOptionableRZLTRezolute4060.54 million49.40 millionOptionableSLRNAcelyrin135100.95 million86.68 millionOptionableTRLPFAcerus Pharmaceuticals29258.62 millionN/ANot OptionableTRLPF, RZLT, SLRN, and FHTX HeadlinesRecent News About These CompaniesTakeda Pharmaceutical Co. Ltd. ADRFebruary 8, 2024 | wsj.comOther OTC Pharmaceuticals - LithuaniaSeptember 17, 2023 | statista.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitJanuary 1, 2023 | seekingalpha.comAcerus Reports Second Quarter 2022 Financial ResultsAugust 9, 2022 | financialpost.comAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 15, 2022 | financialpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRLPF, RZLT, SLRN, and FHTX Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$4.14 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.14 +0.00 (+0.12%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Rezolute NASDAQ:RZLT$3.89 -0.01 (-0.26%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.87 -0.02 (-0.62%) As of 05/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Acelyrin NASDAQ:SLRN$2.27 0.00 (0.00%) As of 05/21/2025Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Acerus Pharmaceuticals OTCMKTS:TRLPF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
